Emergent BioSolutions Inc.

LSE:0IGA Stock Report

Market Cap: US$518.0m

Emergent BioSolutions Past Earnings Performance

Past criteria checks 0/6

Emergent BioSolutions's earnings have been declining at an average annual rate of -60.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 3.5% per year.

Key information

-60.5%

Earnings growth rate

-60.6%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-3.5%
Return on equity-41.1%
Net Margin-18.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Emergent BioSolutions makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0IGA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,126-2093390
30 Jun 241,102-5873430
31 Mar 241,185-5653570
31 Dec 231,049-7603680
30 Sep 231,103-7783610
30 Jun 231,072-6023630
31 Mar 23974-3943510
31 Dec 221,118-2123400
30 Sep 221,491333410
30 Jun 221,581883410
31 Mar 221,7571583520
31 Dec 211,7742203490
30 Sep 211,6532273360
30 Jun 211,7092993300
31 Mar 211,7063873150
31 Dec 201,5773063040
30 Sep 201,3331672890
30 Jun 201,2591702780
31 Mar 201,108682730
31 Dec 191,106552740
30 Sep 191,01642780
30 Jun 19878-182550
31 Mar 19855422230
31 Dec 18782632030
30 Sep 187061001630
30 Jun 186811131560
31 Mar 18562671480
31 Dec 17561831430
30 Sep 17519811310
30 Jun 17512681330
31 Mar 17503611370
31 Dec 16489631430
30 Sep 16497731390
30 Jun 16512941280
31 Mar 165291251190
31 Dec 15489911210
30 Sep 15478791100
30 Jun 15457591150
31 Mar 15460351190
31 Dec 14404541090
30 Sep 14400221090
30 Jun 14351141010
31 Mar 1432419910

Quality Earnings: 0IGA is currently unprofitable.

Growing Profit Margin: 0IGA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0IGA is unprofitable, and losses have increased over the past 5 years at a rate of 60.5% per year.

Accelerating Growth: Unable to compare 0IGA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0IGA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 0IGA has a negative Return on Equity (-41.07%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 19:55
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Emergent BioSolutions Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Robert WassermanBenchmark Company
Louise ChenCantor Fitzgerald & Co.